Clinical trials: Immunologic Deficiency Syndrome
HIV, HIV Infections
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) fixed-dose combination (FDC)…
- Trial name
- NCT01108510
- Testing
- COBI, RTV, ATV
- Where
- 134 sites in United States, Australia and 17 more
- Volunteers
- 698 people
- Sponsor
- Gilead Sciences
Primary Immune Deficiency (PID)
Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)
This study aims to assess the safety, tolerability and pharmacokinetics of Ig NextGen 10% in patients with primary immune deficiency currently being treated with Intragam P.
- Trial name
- NCT00405184
- Testing
- IntragamP, Ig NextGen 10%
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- CSL Limited
HIV Infections
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy…
- Trial name
- NCT06214052
- Testing
- VH4524184, Antiretroviral therapy
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 22 people
- Sponsor
- ViiV Healthcare
HIV Infections
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
- Trial name
- NCT00005918
- Testing
- Efavirenz, Lamivudine, Stavudine
- Where
- 77 sites in United States, Argentina and 14 more
- Volunteers
- 730 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic…
- Trial name
- COOL (NCT00643968)
- Testing
- EFV+TDF, EFV+3TC+TDF
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Immune Thrombocytopenic Purpura ( ITP ), HIV Infections
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura
To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of HIV infection.
- Trial name
- NCT00002250
- Testing
- CD4-IgG
- Where
- United States
- Sponsor
- Genentech, Inc.
HIV Infections
Imaging Immune Activation in HIV by PET-MR
This is a single center exploratory imaging study involving one intravenous microdose of [18F]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine…
- Trial name
- NCT03684655
- Testing
- [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- CellSight Technologies, Inc.
HIV Infections
Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
The purpose of this trial is to determine if exposure to ARV-containing investigational products in IPM clinical trials will impact the natural history of HIV infection as measured by the virologic, immunologic and clinical…
- Trial name
- NCT01618058
- Testing
- No Investigational Product
- Where
- 5 sites in Rwanda, South Africa
- Volunteers
- 151 people
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
- Trial name
- CABNATE (NCT07275606)
- Testing
- Oral CAB, IM CAB LA
- Where
- South Africa
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals
Clinical specimens are required from HIV positive individuals with viremia controlled by antiretroviral therapy to complete process development for a genetically modified autologous T cell product, AGT103-T.
- Trial name
- NCT03215004
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- American Gene Technologies International Inc.
HIV Infections
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
Study to determine the effects of 28 days of nevirapine treatment on the steady-state pharmacokinetics of amprenavir and of abacavir and to further evaluate the pharmacokinetics of nevirapine in combination with amprenavir and…
- Trial name
- NCT02182765
- Testing
- Nevirapine, Amprenavir, Abacavir
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Observational Study of Blood Treated With Cytolin
Primary Objective: To determine the mechanism of Cytolin's effect on HIV replication from blood drawn from HIV-positive and HIV-negative individuals after exposure to Cytolin.
- Trial name
- NCT01048372
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CytoDyn, Inc.
Primary Immunodeficiencies (PID)
Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID)
The purpose of this observational, multi-center, retrospective cohort study is to assess treatment patterns of Cuvitru (SCIG) 20 percent (%) and HyQvia (fSCIG) in polish pediatric participants with PID.
- Trial name
- IG-TATRY (NCT04636502)
- Where
- 5 sites in Poland
- Volunteers
- 96 people
- Sponsor
- Shire
HIV Infections
A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
- Trial name
- NCT00002430
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- 46 sites in United States
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Acquired Immunodeficiency Syndrome
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
Objective: To evaluate the relative bioavailability of a new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare this formulation with the branded formulation (R)…
- Trial name
- NCT02583464
- Testing
- Tenofovir disoproxil fumarate and emtricitabine
- Where
- Argentina
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
Candidiasis, Oral, HIV Infections
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with…
- Trial name
- NCT00002112
- Testing
- Nystatin, Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Healthy Volunteer
GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a proton pump inhibitor, omeprazole, to…
- Trial name
- NCT00942136
- Testing
- GSK1349572, Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Leukoplakia, Hairy, HIV Infections
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL).
- Trial name
- NCT00002026
- Testing
- Acyclovir
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV Infections
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations.
- Trial name
- NCT00189904
- Testing
- IMVAMUNE (MVA-BN)
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- Bavarian Nordic
HIV, HIV-1
Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.
The purpose of this study is to evaluate the non-inferiority of ritonavir-boosted GS-9137 relative to a ritonavir-boosted Comparator Protease Inhibitor when used as part of combination antiretroviral regimens in subjects who have…
- Conditions
- HIV, HIV-1, Human Immunodeficiency Virus
- Trial name
- NCT00298350
- Testing
- GS-9137 - A Novel HIV-1 Integrase Inhibitor
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 278 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.